| Bioactivity | Yadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS (HY-D1056)-induced acute lung injury (ALI) in mice[1]. |
| Invitro | Yadanzigan (20, 40, 80 μM; 1 h) 促进 RAW264.7 巨噬细胞的 Nrf2 从细胞质转位到细胞核[1]。Yadanzigan (20 μM; 1 h) 抑制 LPS 诱导 HEK293T 细胞线粒体活性氧 (ROS) 的生成 (1 μg/mL; 6 h)[1]。Yadanzigan (40 μM; 1 h) 显著阻断 J774A 细胞在LPS和ATP诱导下 NLRP3 炎性小体的形成[1]。Yadanzigan (2.5-10 μM 或 10-40 μM; 1, 6, 12 h) 增强J774A.1 和 THP-1 细胞中 TRIM31 表达，促进 NLRP3 蛋白降解[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Yadanzigan 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | Yadanzigan (5 mg/kg, 10 mg/kg; 静脉注射; 共 3 次) 预防 LPS 诱导的小鼠急性肺损伤[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 76588-87-9 |
| Formula | C26H38O14 |
| Molar Mass | 574.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Cui Y, et al. Yadanzigan, a quassinoid glucoside, attenuates NLRP3 inflammasome activation to prevent LPS-induced acute lung injury. Authorea Preprints, 2020. |